SGLT2 Inhibitor, Canagliflozin, Attenuates Myocardial Infarction in the Diabetic and Nondiabetic Heart

The authors hypothesized that despite similar cardiovascular event rates, the improved cardiovascular survival from sodium glucose transporter 2 (SGLT2) inhibition, seen clinically, could be via a direct cytoprotective effect, including protection against myocardial ischemia/reperfusion injury. Lang...

Descripción completa

Detalles Bibliográficos
Autores principales: Lim, Ven G., Bell, Robert M., Arjun, Sapna, Kolatsi-Joannou, Maria, Long, David A., Yellon, Derek M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2019
Materias:
MINI FOCUS ON SGLT2 INHIBITOR
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6390729/
https://www.ncbi.nlm.nih.gov/pubmed/30847415
http://dx.doi.org/10.1016/j.jacbts.2018.10.002

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6390729/
https://www.ncbi.nlm.nih.gov/pubmed/30847415
http://dx.doi.org/10.1016/j.jacbts.2018.10.002

Ejemplares similares